Dermira, Inc. (DERM) Receives Consensus Rating of “Hold” from Analysts

Shares of Dermira, Inc. (NASDAQ:DERM) have been given a consensus recommendation of “Hold” by the eleven research firms that are covering the company, MarketBeat reports. Five investment analysts have rated the stock with a sell rating and six have issued a buy rating on the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $43.33.

A number of brokerages have recently commented on DERM. Zacks Investment Research cut shares of Dermira from a “hold” rating to a “sell” rating in a research note on Thursday, November 9th. Leerink Swann reissued an “outperform” rating and issued a $41.00 price target (down previously from $47.00) on shares of Dermira in a research note on Tuesday, November 7th. Needham & Company LLC reissued a “buy” rating and issued a $43.00 price target (down previously from $46.00) on shares of Dermira in a research note on Tuesday, November 7th. Cantor Fitzgerald reissued a “buy” rating and issued a $45.00 price target on shares of Dermira in a research note on Monday, November 6th. Finally, Mizuho reissued a “buy” rating and issued a $43.00 price target (up previously from $40.00) on shares of Dermira in a research note on Thursday, September 7th.

In other Dermira news, insider Eugene A. Bauer sold 7,500 shares of the firm’s stock in a transaction on Wednesday, October 11th. The stock was sold at an average price of $30.04, for a total value of $225,300.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Thomas G. Wiggans sold 9,500 shares of the firm’s stock in a transaction on Monday, September 18th. The shares were sold at an average price of $27.51, for a total value of $261,345.00. The disclosure for this sale can be found here. Insiders sold a total of 29,400 shares of company stock worth $822,553 in the last three months. 13.30% of the stock is owned by corporate insiders.

Hedge funds have recently made changes to their positions in the business. BNP Paribas Arbitrage SA lifted its holdings in Dermira by 2,220.7% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 4,154 shares of the biopharmaceutical company’s stock valued at $121,000 after purchasing an additional 3,975 shares in the last quarter. Quantbot Technologies LP lifted its holdings in Dermira by 75.4% in the 3rd quarter. Quantbot Technologies LP now owns 5,371 shares of the biopharmaceutical company’s stock valued at $145,000 after purchasing an additional 2,309 shares in the last quarter. SG Americas Securities LLC lifted its holdings in Dermira by 66.8% in the 2nd quarter. SG Americas Securities LLC now owns 5,503 shares of the biopharmaceutical company’s stock valued at $160,000 after purchasing an additional 2,203 shares in the last quarter. KCG Holdings Inc. purchased a new position in Dermira in the 1st quarter valued at $215,000. Finally, Legal & General Group Plc lifted its holdings in Dermira by 16.3% in the 1st quarter. Legal & General Group Plc now owns 6,861 shares of the biopharmaceutical company’s stock valued at $236,000 after purchasing an additional 963 shares in the last quarter. Institutional investors own 98.09% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another domain, it was stolen and reposted in violation of international trademark & copyright laws. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2017/12/04/dermira-inc-derm-receives-consensus-rating-of-hold-from-analysts.html.

Shares of Dermira (NASDAQ DERM) opened at $24.44 on Friday. Dermira has a one year low of $21.35 and a one year high of $38.75. The company has a current ratio of 4.68, a quick ratio of 4.68 and a debt-to-equity ratio of 1.40.

Dermira Company Profile

Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.

Analyst Recommendations for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply